Healthcare Aug 02, 2021 08:36 AM (GMT+8) · EqualOcean
Xinkaiyuan announced that its subsidiary, xinkaiyuan biology, will sell its 100% equity of nkyus to Abcam us, a subsidiary of Abcam. The estimated transaction price is US $343 million. The final transaction price is expected to be no less than the preliminary estimated amount. This transaction is expected to constitute a major asset reorganization. NKY us is a special purpose company indirectly holding biovision established by a listed company in Delaware, USA. its main assets are 100% equity of biovision.